Characteristics and outcomes of patients treated with tigecycline for MDR gram-negative infections: a retrospective cohort study
Frontiers in Cellular and Infection Microbiology · 01.04.2026 · 16
DOI: 10.3389/fcimb.2026.1790441 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Frontiers in Cellular and Infection Microbiology, online erschienen am 01.04.2026. Verfasst von Shuroug A Alowais und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice, College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia. Hauptthemen laut MEDLINE: Tigecycline, Anti-Bacterial Agents, Drug Resistance, Multiple, Bacterial, Gram-Negative Bacterial Infections. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Multidrug-resistant (MDR) gram-negative pathogens pose a major therapeutic challenge, particularly in settings with limited antimicrobial options. Tigecycline is frequently used as salvage therapy. However, evidence regarding the optimal tigecycline regimen, whether used as monotherapy or in combination, remains uncertain. This study aimed to describe the characteristics, clinical, and microbiological outcomes of these cases.
Methods
Retrospective, single-center study of adult hospitalized patients treated with tigecycline for MDR Acinetobacter baumannii , extended-spectrum β-lactamase (ESBL)-producing Escherichia coli , and ESBL- or Carbapenem-Resistant Enterobacterales Klebsiella pneumoniae . Patients were categorized into tigecycline monotherapy or combination therapy groups. The primary outcomes were clinical success and 30-day mortality. Multivariable logistic regression was used to identify predictors of outcomes. A sensitivity analysis excluding bloodstream and urinary tract infections was performed due to pharmacokinetic limitations of tigecycline.
Results
Two hundred eighty were included; 116 (41.4%) received tigecycline monotherapy and 164 (58.6%) received combination therapy. Patients receiving combination therapy had higher illness severity and higher intensive care unit admissions. Overall clinical success was achieved in 53.2% of patients with a higher rate in the monotherapy group (64.7%, p = 0.001), and 30-day mortality was 26.1%. After adjustment, tigecycline monotherapy was not independently associated with clinical success or mortality. Sensitivity analyses excluding bloodstream and urinary tract infections showed consistent results.
Conclusion
In this real-world cohort of severely ill patients with MDR gram-negative infections, no outcome advantage was observed with tigecycline combination therapy after adjustment. Clinical outcomes were primarily driven by illness severity and infection characteristics rather than treatment strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy Practice, College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
- King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.
- Ministry of the National Guard - Health Affairs, Riyadh, Saudi Arabia.
- Department of Clinical Pharmacy, College of Pharmacy, University of Ha'il, Ha'il, Saudi Arabia.
- Department of Pharmacy Practice, College of Clinical Pharmacy, King Faisal University, Al-Ahsa, Saudi Arabia.
- Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
Zitieren
APA
Alowais, S. A., Aldairem, A., Bin Saleh, K., Alsowaida, Y. S., Alharbi, M. M., Wali, H. A., & Almangour, T. A. (2026). Characteristics and outcomes of patients treated with tigecycline for MDR gram-negative infections: a retrospective cohort study. Frontiers in Cellular and Infection Microbiology, 16. https://doi.org/10.3389/fcimb.2026.1790441
Vancouver
Alowais SA, Aldairem A, Bin Saleh K, Alsowaida YS, Alharbi MM, Wali HA, et al. Characteristics and outcomes of patients treated with tigecycline for MDR gram-negative infections: a retrospective cohort study. Frontiers in Cellular and Infection Microbiology. 2026;16. doi:10.3389/fcimb.2026.1790441
BibTeX
@article{Alowais2026,
author = {Alowais, Shuroug A and Aldairem, Atheer and Bin Saleh, Khalid and Alsowaida, Yazed S and Alharbi, Muhannad Musaad and Wali, Haytham A and Almangour, Thamer A},
title = {Characteristics and outcomes of patients treated with tigecycline for MDR gram-negative infections: a retrospective cohort study},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2026},
volume = {16},
doi = {10.3389/fcimb.2026.1790441}
}
EUVIMED